FDA approves Zembrace SymTouch

Dr. Reddy’s Laboratories Ltd. Receives FDA Approval for Zembrace SymTouch (sumatriptan succinate) Injection for the Acute Treatment of Migraines
Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that the U.S. Food and Drug Administration (FDA) has approved Zembrace SymTouch (sumatriptan succinate) injection, a drug-device combination product intended for the treatment of acute migraine episodes, with or without aura, in adults who are inadequately managed with existing treatment regimens. Zembrace SymTouch is available as a prefilled, ready-to-use, single-dose disposable autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. The injection is intended to be given subcutaneously.
“We are pleased to have received FDA approval for Zembrace SymTouch,” said Raghav Chari, Executive Vice President, Proprietary Products Group at Dr. Reddy’s Laboratories. “Zembrace SymTouch is the first branded product in our Neurology portfolio.
Migraine affects millions of patients. Many of these patients have busy lives and quick pain relief is critical to help them manage through their daily routines. In many cases, migraine episodes are accompanied by severe nausea, making it difficult to swallow and retain pills.
Zembrace SymTouch is specifically designed for patients who may experience certain migraine episodes and for whom a pill may not be the right option.”
Source: drugs.com

 

FDA approves Zembrace SymTouch

Dr. Reddys Laboratories Ltd. Receives FDA Approval for Zembrace SymTouch (sumatriptan succinate) Injection for the Acute Treatment of Migraines Dr. Reddys Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that the U.S. Food and Drug Administration (FDA) has approved Zembrace SymTouch (sumatriptan succinate) injection, a drug-device combination product intended for the treatment of acute migraine episodes, with or without aura, in adults who are inadequately managed with existing treatment regimens. Zembrace SymTouch is available as a prefilled, ready-to-use, single-dose disposable autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. The injection is intended to be given subcutaneously. We are pleased to have received FDA approval for Zembrace SymTouch, said Raghav Chari, Executive Vice President, Proprietary Products Group at Dr. Reddys Laboratories. Zembrace SymTouch is the first branded product in our Neurology portfolio. Migraine affects millions of patients. Many of these patients have busy lives and quick pain relief is critical to help them manage through their daily routines. In many cases, migraine episodes are accompanied by severe nausea, making it difficult to swallow and retain pills. Zembrace SymTouch is specifically designed for patients who may experience certain migraine episodes and for whom a pill may not be the right option. Source: drugs.com